Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review

Cardiovascular disease (CVD) is the leading cause of mortality worldwide yet, despite advances in treatment, CVD remains an underestimated and undermanaged condition, with an even greater risk in Type 2 Diabetes Mellitus (T2DM). Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) are a promising nov...

Descripción completa

Detalles Bibliográficos
Autores principales: Georgiou, Petros, Shi, Wangpan, Serhiyenia, Tatsiana, Akram, Aqsa, Proute, Matthew C, Pradeep, Roshini, Kerolos, Mina E, Khan, Safeera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569689/
https://www.ncbi.nlm.nih.gov/pubmed/34754647
http://dx.doi.org/10.7759/cureus.18485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569689/
https://www.ncbi.nlm.nih.gov/pubmed/34754647
http://dx.doi.org/10.7759/cureus.18485

Ejemplares similares